Vir Biotechnology Stock News

Equities research analysts expect Vir Biotechnology, Inc. (NASDAQ:VIR) to announce sales of $152.16 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Vir Biotechnologys earnings, with the lowest sales estimate coming in at $124.21 million and the highest estimate coming in at $180.10 million. Vir Biotechnology reported sales of []

NEW YORK , Nov. 26, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, BNTX, CARS, TDOC, and PFE. Full story available on Benzinga.com

Black Friday Turns Red On "Terrible News" - Global Markets Crater On "Nu Variant" Panic The Friday after thanksgiving is called black Friday because that''s when retailers finally turn profitable for the year. Not so much for market, however, because this morning it''s red as far as the eye can see. The culprit: the same one we discussed late last night - the emergence of a new coronavirus strain detected in South Africa, known as B.1.1.529, which reportedly carries an "extremely high number" of mutations and is “clearly very different” from previous incarnations, which may drive further waves of disease by evading the body’s defenses according to South African scientists, and soon, Anthony Fauci. British authorities think it is the most significant variant to date and have hurried to impose travel restrictions on southern Africa, as did Japan, the Czech Republic and Italy on Friday. The European Union also said it aimed to halt air travel from the region. "Markets have been quite complacent about the pandemic for a while, partly because economies have been able to withstand the impact of selective lockdown measures.

Related Stocks: SPYG , SPYV , SCHG , VEA , VO , IJR , FCTR , DFAT , DFAI , IYW , DEN , WFHY , VIG , BGLD , PTON , KMB , GOVT , MTUM , MRVI , 41W0 , DNL , QDEF , VIR , WKHS ,

Equities research analysts forecast that Vir Biotechnology, Inc. (NASDAQ:VIR) will post earnings of $0.90 per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Vir Biotechnologys earnings, with the highest EPS estimate coming in at $4.52 and the lowest estimate coming in at ($0.99). Vir Biotechnology posted []

Bank of America Corp DE lifted its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 30.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 233,674 shares of the companys stock after buying an additional 54,888 shares during the quarter. Bank of []

Man Group plc lifted its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 9.5% during the second quarter, Holdings Channel.com reports. The fund owned 8,008 shares of the companys stock after purchasing an additional 695 shares during the period. Man Group plcs holdings in Vir Biotechnology were worth $378,000 at the end of the []

Vir Biotechnology Inc. (NASDAQ:VIR) price on Friday, November 19, rose 3.34% above its previous days close as an upside momentum from buyers pushed the stocks value to $32.75. A look at the stocks price movement, the close in the last trading session was $31.69, moving within a range at $31.75 and $33.19. Turning to its Vir Biotechnology Inc. (NASDAQ: VIR): The Metrics That Matter Right Now Read More »

Needham & Company LLC restated their buy rating on shares of Vir Biotechnology (NASDAQ:VIR) in a report published on Wednesday morning, Price Targets.com reports. They currently have a $79.00 target price on the stock. A number of other research analysts have also weighed in on the company. TheStreet lowered Vir Biotechnology from a c- rating []

Vir Biotechnology, Inc. (NASDAQ:VIR) insider Phillip Pang sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 17th. The stock was sold at an average price of $35.85, for a total value of $179,250.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is […]

GlaxoSmithKline (GSK) and Vir Biotechnology have secured contracts from the US government for nearly $1bn to supply their Covid-19 antibody treatment, sotrovimab. Sotrovimab is an investigational single-dose SARS-CoV-2 The post GSK and Vir to supply Covid-19 antibody treatment doses to US appeared first on Pharmaceutical Business review .

Glaxo (GSK) and Vir Biotechnology (VIR) sign purchase contract with the U.S. government to supply doses of sotrovimab worth approximately $1 billion by next month.

Needham & Company LLC reissued their buy rating on shares of Vir Biotechnology (NASDAQ:VIR) in a research report sent to investors on Wednesday, PriceTargets.com reports. They currently have a $79.00 target price on the stock. Several other research firms also recently issued reports on VIR. Barclays decreased their price objective on shares of Vir Biotechnology []

Britains GlaxoSmithKline plc (LON: GSK) announced in a joint statement with the U.S. based Vir Biotechnology Inc (NASDAQ: VIR) on Wednesday that the U.S. government had agreed to buy about $1.0 billion worth of its antibody-based COVID-19 treatment. U.S. wants GSK to deliver the doses by December 17th The number of doses of Sotrovimab [] The post U.S. places a sizable order for GSK-Virs COVID-19 treatment appeared first on Invezz .